Ohr Pharma appoints new director
This article was originally published in Scrip
New York-based Ohr Pharmaceutical, which is currently developing treatments for the wet form of age-related macular degeneration and for cancer cachexia, has appointed Dr Thomas Riedhammer to its board of directors. Most recently, Dr Riedhammer was chair of Sirion Therapeutics. Prior to Sirion, he was chief operating officer at Presby, a medical device company which develops treatments for eye disorders.